Completed from United Kingdom
I took this course because I wanted a solid grounding in health economics before moving into pharma consulting. It was spot‑on – the lectures were clear, the real‑world UK case studies (like the NHS drug reimbursement model) made the theory click. I especially loved the hands‑on Excel worksheets where we built a simple budget impact model; I’ve already used that template at work. The course material was well‑organized and the video recordings were easy to follow. It was a great mix of rigorous content and practical tools, and I left feeling ready to take on client projects.
The Pharmaceutical Health Economics course at Stanmore School of Business precisely matched my learning objectives. The modules on cost‑effectiveness analysis gave me the confidence to develop a full economic evaluation for a new oncology drug, which I later presented to my employer’s senior management. The case studies were up‑to‑date and directly relevant to the U.S. healthcare market, and the supplemental reading pack included the latest CMS guidelines. The instructor’s feedback on my assignments was prompt and professional, helping me refine my modelling skills. Overall, the experience exceeded my expectations and I feel fully equipped to contribute to strategic pricing decisions.
Wow! This course blew me away! I was looking for something that could bridge the gap between my MPH and a career in pharma, and Stanmore delivered. The segment on health technology assessment gave me the exact steps to conduct a HTA report for a biosimilar, and I even got to practice writing an executive summary that my professor praised. The videos were lively, the quizzes were fun, and the discussion forum sparked great conversations with peers from all over the world. I can already see the impact – I’ve been asked to lead a cost‑utility analysis at my hospital. Absolutely loved the experience!
The Pharmaceutical Health Economics module was exceptionally detailed and aligned well with my goal of entering the pharmaceutical pricing sector in South Africa. The curriculum covered everything from basic economic theory to advanced budget impact modelling, and each concept was reinforced with comprehensive slide decks and real‑world data sets from both high‑income and low‑income markets. A standout was the group project where we simulated pricing negotiations for a malaria vaccine, which taught me negotiation tactics and stakeholder analysis. The instructor’s thorough explanations and the availability of supplementary reading materials made the learning curve manageable. I left the course with a robust analytical toolkit and a clear roadmap for applying these skills in my current role.
